Dr. Salles on Frontline Management of Follicular Lymphoma

Gilles Salles, MD, PhD
Published: Tuesday, Feb 28, 2017



Gilles Salles, MD, PhD, Centre Hospitalier Lyon-Sud, discusses frontline treatment management for patients with follicular lymphoma.

For patients who are asymptomatic, observation is usually the optimal way to start treatment, says Salles. While rituximab (Rituxan) is effective in most patients with follicular lymphoma, those who are asymptomatic showed little benefit from rituximab maintenance in clinical trials.

But, patients who are symptomatic or have a high tumor burden have responded well to rituximab maintenance. In this setting, it has been shown to improve progression-free survival, but not overall survival (OS). Although OS is not improved, this treatment option is still important to consider as it improves the day-to-day management of the disease, says Salles.

New agents such as obinutuzumab (Gazyva) and the combination of rituximab plus lenalidomide (Revlimid) are currently being investigated in this setting, as well.
 


Gilles Salles, MD, PhD, Centre Hospitalier Lyon-Sud, discusses frontline treatment management for patients with follicular lymphoma.

For patients who are asymptomatic, observation is usually the optimal way to start treatment, says Salles. While rituximab (Rituxan) is effective in most patients with follicular lymphoma, those who are asymptomatic showed little benefit from rituximab maintenance in clinical trials.

But, patients who are symptomatic or have a high tumor burden have responded well to rituximab maintenance. In this setting, it has been shown to improve progression-free survival, but not overall survival (OS). Although OS is not improved, this treatment option is still important to consider as it improves the day-to-day management of the disease, says Salles.

New agents such as obinutuzumab (Gazyva) and the combination of rituximab plus lenalidomide (Revlimid) are currently being investigated in this setting, as well.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x